Sold as Deca-Durabolin. Every FDA application for this active ingredient: 1 branded and 13 generic.
As of Nov 15, 2026, FDA lists 14 applications for Nandrolone Decanoate (sold as Deca-Durabolin), first approved Oct 5, 1962, with 0 new uses approved and 0 published complete response letters.
| Impact of Medically Supervised Performance-Enhancing Substances (PES) on Elite AthletesSafety and Impact of Medically Supervised Performance Enhancing Substance Usage in Healthy Elite Athletes · Enhanced Emirates Limited | Not applicable | Enrolling by invitation | May 6, 2026 |
| Peri-Operative Testosterone Administration in Primary Total Hip ArthroplastyOsteoarthritis, Hip · American Hip Institute | Phase 4 | Not yet recruiting | Sep 23, 2024 |
| Peri-Operative Testosterone Administration in Primary Hip ArthroscopyFemoro Acetabular Impingement · American Hip Institute | Phase 4 | Not yet recruiting | Jun 17, 2024 |
| Study of the Effectiveness of Treatment of Sarcopenia With the Use of a Medicinal Product (Nandrolone), Comprehensive Physiotherapy and DietSarcopenia · National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland | Phase 2 | Recruiting | Aug 7, 2023 |
| Oct 5, 1962 | Deca-DurabolinNDA 13132 · New active ingredient | Woodward Specl | 8 | Discontinued |
| Oct 14, 1983 | Nandrolone DecanoateANDA 88317 | Abraxis Pharm | 2 | Discontinued |
| Dec 5, 1983 | Nandrolone DecanoateANDA 88128 | Watson Labs | 17 | Discontinued |
| Jan 13, 1984 | Nandrolone DecanoateANDA 86385 | Watson Labs | 20 | Discontinued |
| Jan 13, 1984 | Nandrolone DecanoateANDA 86598 | Watson Labs | 21 | Discontinued |
| Aug 30, 2010 | Nandrolone DecanoateANDA 91252 | Am Regent | 0 | Discontinued |
| — | Nandrolone DecanoateANDA 87519 | Epic Pharma LLC | 0 | Discontinued |
| — | Nandrolone DecanoateANDA 87598 | Watson Labs | 0 | Discontinued |
| — | Nandrolone DecanoateANDA 87599 | Watson Labs | 0 | Discontinued |
| — | Nandrolone DecanoateANDA 88290 | Abraxis Pharm | 2 | Discontinued |
| — | Nandrolone DecanoateANDA 88554 | Watson Labs | 0 | Discontinued |
| — | Nandrolone DecanoateANDA 89248 | Quad Pharms | 0 | Discontinued |
| — | Nandrolone DecanoateANDA 89249 | Quad Pharms | 0 | Discontinued |
| — | Nandrolone DecanoateANDA 89250 | Quad Pharms | 0 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
Abraxis Pharm